Altamira Therapeutics Ltd (ID) (CYTOF)

Altamira Therapeutics Announces Publication Highlighting Potential of RNA Nanoparticles for Disease-Modifying Treatment of Osteoarthritis

HAMILTON, BM / ACCESS Newswire / April 13, 2026 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCID:CYTOF), a...

Altamira Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results

Expanding nucleic acid delivery business with new applicationsOngoing optimization of cost structureAdvancing plans for spin-off of nucleic acid...

Altamira Therapeutics Announces Release Date for 2025 Annual Report and Financial Statements

HAMILTON, BM / ACCESS Newswire / March 24, 2026 / Altamira Therapeutics ("Altamira" or the "Company") (OTCID:CYTOF) today...

Form 15-12G - Securities registration termination [Section 12(g)]

Altamira Therapeutics Announces Allowance of Japanese Patent Application Covering Bentrio Nasal Spray

HAMILTON, BM / ACCESS Newswire / February 13, 2026 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCID:CYTOF), a...

Altamira Therapeutics to Present at mRNA-Based Therapeutics Summit

HAMILTON, BERMUDA / ACCESS Newswire / January 23, 2026 / Altamira Therapeutics Ltd. ("Altamira" or the "Company"...

Altamira Therapeutics Announces Market Approval of Bentrio Nasal Spray in China

Regulatory clearance of Bentrio in allergic rhinitis for Mainland ChinaNearly 200 million Chinese estimated to suffer from allergic...

Altamira Therapeutics Announces Certification of Bentrio Nasal Spray under Medical Device Regulation

Conformity with stringent new EU regulations for medical devices confirmedAllows for commercialization of Bentrio in EU member states; facilitates...

Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of DNA Molecules

Demonstrated feasibility of effective DNA delivery with Company's xPhore™ nanoparticle technologyDNA delivery technology to be offered...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]